Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer.

ABSTRACT: In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to a successful combinatorial immunotherapy treatment implies knowledge of the immune changes that are induced by chemotherapy and surgery.

Methodology

Patients with a new d ovarian cancer diagnosis underwent longitudinal blood samples at different time points during primary treatment.

Results

Ninety patients were included in the study (33% primary debulking surgery (PDS) with adjuvant chemotherapy (ACT), 61% neo-adjuvant chemotherapy (NACT) with interval debulking surgery (IDS), and 6% debulking surgery only). Reductions in immunosuppression were observed after NACT, but surgery reverted this effect. The immune-related proteins showed a pronounced decrease in immune stimulation and immunosuppr

SUBMITTER: De Bruyn C 

PROVIDER: S-EPMC8656504 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature